Filing Details

Accession Number:
0001104659-11-064968
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-11-17 19:36:24
Reporting Period:
2011-11-16
Filing Date:
2011-11-17
Accepted Time:
2011-11-17 19:36:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1466301 Clovis Oncology Inc. CLVS Pharmaceutical Preparations (2834) 900475355
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1266567 G Brian Atwood C/O Versant Ventures
3000 Sand Hill Road, Bldg 4, Suite 210
Menlo Park CA 94025
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-16 661,323 $0.00 2,159,289 No 4 P Indirect See Footnote
Common Stock Acquisiton 2011-11-16 4,165 $0.00 13,600 No 4 P Indirect See Footnote
Common Stock Option Acquisiton 2011-11-16 45,171 $0.00 45,171 No 4 J Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 J Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Convertible Preferred Stock Acquisiton 2011-11-16 295,404 $0.00 295,404 $0.00
Common Stock Series A-1 Convertible Preferred Stock Acquisiton 2011-11-16 1,861 $0.00 1,861 $0.00
Common Stock Series A-2 Convertible Preferred Stock Acquisiton 2011-11-16 295,404 $0.00 295,404 $0.00
Common Stock Series A-2 Convertible Preferred Stock Acquisiton 2011-11-16 1,861 $0.00 1,861 $0.00
Common Stock Series B Convertible Preferred Stock Acquisiton 2011-11-16 639,403 $0.00 639,403 $0.00
Common Stock Series B Convertible Preferred Stock Acquisiton 2011-11-16 4,027 $0.00 4,027 $0.00
Common Stock Convertible Promissory Note Acquisiton 2011-11-16 267,755 $0.00 267,755 $0.00
Common Stock Convertible Promissory Note Acquisiton 2011-11-16 1,686 $0.00 1,686 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock on a 1 for 1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date.
  2. Each share of Series A-2 Convertible Preferred Stock automatically converted into shares of Common Stock on a 1 for 1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date.
  3. Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1 for 1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date.
  4. The outstanding principal amount and all accrued and unpaid interest automatically converted into Common Stock at a rate of $13.00 per share, which was the Company's initial public offering price.
  5. The shares are held by Versant Venture Capital IV, L.P. ("Versant IV"). In their capacity as managing members of Versant Ventures IV, LLC which is the general partner of Versant IV, Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Kirk G. Nielsen share voting and investment authority over the shares held by the Versant IV and may be deemed to beneficially own the shares. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Kirk G. Nielsen disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein.
  6. The shares are held by Versant Side Fund IV, L.P. ("Versant Side"). In their capacity as managing members of Versant Ventures IV, LLC which is the general partner of Versant Side, Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Kirk G. Nielsen share voting and investment authority over the shares held by the Versant Side and may be deemed to beneficially own the shares. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Kirk G. Nielsen disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein.
  7. The shares are held by Brian G. Atwood (the "Reporting Person"). The Reporting Person is a Managing Director of Versant Ventures IV, LLC, which serves as the general partner of Versant Venture Capital IV, L.P. and Versant Side Fund IV, L.P. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein.